Norris Perne & French LLP MI Boosts Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

Norris Perne & French LLP MI boosted its stake in Thermo Fisher Scientific Inc. (NYSE:TMOFree Report) by 42.5% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 36,770 shares of the medical research company’s stock after acquiring an additional 10,962 shares during the period. Thermo Fisher Scientific accounts for about 1.5% of Norris Perne & French LLP MI’s holdings, making the stock its 24th biggest position. Norris Perne & French LLP MI’s holdings in Thermo Fisher Scientific were worth $19,517,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in TMO. Moneta Group Investment Advisors LLC increased its position in Thermo Fisher Scientific by 104,536.8% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 8,355,245 shares of the medical research company’s stock valued at $4,601,150,000 after acquiring an additional 8,347,260 shares during the period. Providence Capital Advisors LLC increased its position in Thermo Fisher Scientific by 61,754.7% in the 1st quarter. Providence Capital Advisors LLC now owns 5,842,175 shares of the medical research company’s stock valued at $10,136,000 after acquiring an additional 5,832,730 shares during the period. Norges Bank acquired a new position in Thermo Fisher Scientific in the 4th quarter valued at about $3,105,677,000. Morgan Stanley increased its position in Thermo Fisher Scientific by 17.7% in the 4th quarter. Morgan Stanley now owns 11,730,063 shares of the medical research company’s stock valued at $6,459,629,000 after acquiring an additional 1,764,312 shares during the period. Finally, Loomis Sayles & Co. L P increased its position in Thermo Fisher Scientific by 17,046.7% in the 3rd quarter. Loomis Sayles & Co. L P now owns 973,591 shares of the medical research company’s stock valued at $492,803,000 after acquiring an additional 967,913 shares during the period. Institutional investors and hedge funds own 89.23% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the company. TheStreet upgraded Thermo Fisher Scientific from a “c+” rating to a “b-” rating in a research report on Friday, December 22nd. Citigroup assumed coverage on Thermo Fisher Scientific in a research report on Monday, March 18th. They set a “neutral” rating and a $620.00 target price on the stock. Royal Bank of Canada boosted their target price on Thermo Fisher Scientific from $592.00 to $642.00 and gave the stock an “outperform” rating in a research report on Thursday, February 1st. HSBC started coverage on Thermo Fisher Scientific in a report on Monday, December 18th. They issued a “buy” rating and a $610.00 price target on the stock. Finally, Raymond James upped their price target on Thermo Fisher Scientific from $515.00 to $605.00 and gave the stock an “outperform” rating in a report on Thursday, February 1st. Five analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $599.00.

Read Our Latest Analysis on Thermo Fisher Scientific

Thermo Fisher Scientific Stock Down 0.6 %

Shares of NYSE TMO opened at $577.73 on Tuesday. Thermo Fisher Scientific Inc. has a 12-month low of $415.60 and a 12-month high of $603.82. The company has a market cap of $220.29 billion, a P/E ratio of 37.39, a P/E/G ratio of 2.44 and a beta of 0.80. The company has a current ratio of 1.75, a quick ratio of 1.39 and a debt-to-equity ratio of 0.67. The stock has a fifty day moving average price of $566.95 and a 200 day moving average price of $521.68.

Thermo Fisher Scientific (NYSE:TMOGet Free Report) last announced its quarterly earnings results on Wednesday, January 31st. The medical research company reported $5.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.64 by $0.03. Thermo Fisher Scientific had a return on equity of 18.78% and a net margin of 13.99%. The firm had revenue of $10.89 billion during the quarter, compared to the consensus estimate of $10.73 billion. During the same period in the prior year, the firm earned $5.40 EPS. The firm’s quarterly revenue was down 4.9% compared to the same quarter last year. Research analysts anticipate that Thermo Fisher Scientific Inc. will post 21.52 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, April 15th. Stockholders of record on Friday, March 15th will be paid a dividend of $0.39 per share. The ex-dividend date is Thursday, March 14th. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. This represents a $1.56 annualized dividend and a dividend yield of 0.27%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.10%.

Insider Activity

In other news, SVP Michael A. Boxer sold 14,566 shares of the stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the transaction, the senior vice president now owns 12,901 shares of the company’s stock, valued at $7,250,362. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 14,566 shares of the firm’s stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total value of $8,186,092.00. Following the transaction, the senior vice president now owns 12,901 shares of the company’s stock, valued at $7,250,362. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Debora L. Spar sold 164 shares of the firm’s stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $546.97, for a total transaction of $89,703.08. Following the completion of the transaction, the director now directly owns 1,207 shares in the company, valued at approximately $660,192.79. The disclosure for this sale can be found here. Insiders sold 50,277 shares of company stock worth $28,513,384 over the last ninety days. Corporate insiders own 0.32% of the company’s stock.

About Thermo Fisher Scientific

(Free Report)

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Read More

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.